- News
- Announcements
Announcements
Current & archive
Horizon Scanning in Oncology - Fact Sheets
We are pleased to introduce you four new Fact Sheets.
Fact Sheet No. 180 (June 2024)
Erdafitinib (Balversa®) as monotherapy for the treatment of unresectable or metastatic urothelial carcinoma (UC)
Fact Sheet No. 181 (June 2024)
Odronextamab (Ordspono®) as monotherapy for the treatment of relapsed or refractory follicular lymphoma (r/r FL) or diffuse large B?cell lymphoma (r/r DLBCL)
Fact Sheet No. 183 (June 2024)
Epcoritamab (Tepkinly®) as monotherapy for the treatment of relapsed or refractory follicular lymphoma (FL)
Stereotactic radiotherapy, proton therapy and irreversible electroporation for the treatment of localised prostate cancer
This update report assesses three alternative treatments to radical therapies for localised prostate cancer (PCA): irreversible electroporation (IRE) uses electrode needles to target and destroy carcinoma tissue; stereotactic radiation therapy (SBRT) and proton therapy (PT) are forms of external beam radiation therapy, SBRT delivers high dose radiation in fewer fractions than conventional or moderate fractionation radiation, while PT delivers high-dose ionizing radiation with great precision.
The current evidence remains insufficient to conclude that IRE, SBRT, and PT improve outcomes in terms of survival and quality of life, as well as the avoidance of radical invasive procedures like prostatectomy, compared to conventional therapies. Recent RCTs on SBRT show minor differences in survival rates compared to conventional fractionation radiation in low- and intermediate-risk PCa. Further research is necessary for definitive conclusions.
Publication: Project Report No.: 107/1. Update: https://eprints.aihta.at/1530/
Contact: Judit Erdös
Evaluation of individual medical procedures - Reports 2024
We are pleased to introduce our new reports.
Decision Support Documents 2024:
- DSD 139: Caval valve implantation for severe tricuspid regurgitation https://eprints.aihta.at/1525
- DSD 140: Electroconvulsive therapy in treatment-resistant depression and treatment-resistant schizophrenia https://eprints.aihta.at/1526
- DSD 141: Thermoablation for benign thyroid nodules https://eprints.aihta.at/1527
+ 2 Updates
- DSD 24: Percutaneous transluminal coronary angioplasty (PTCA) with drug-eluting balloon (DEB) in patients with coronary artery disease (CAD). 3. Update 2024 https://eprints.aihta.at/1528
- DSD 45: Renal denervation (RDN) in patients with treatment resistant hypertension. 2. Update 2024 https://eprints.aihta.at/1529
Point of Care Tests (POCT): D-Dimer and Troponin. Update 2024
Point of care tests (POCTs) for troponin (Tn) and D-Dimer enable rapid diagnostics near patients. Tn-POCTs are used when there is a suspicion of acute coronary syndrome (ACS) and D-Dimer-POCTs are used when there is a suspicion of venous thromboembolism (VTE).
The aim of this report is to evaluate the clinical utility of the two POC diagnostics, D-Dimer and troponin, in primary care.
Publication: HTA Project Report No. 124, 1. Update 2024: https://eprints.aihta.at/1524/
Contact: Claudia Wild
Horizon Scanning in Oncology - Fact Sheets
We are pleased to introduce you three new Fact Sheets.
Fact Sheet No. 177 (May 2024)
Sugemalimab (Cejemly®) with platinum-based chemotherapy for the first?line treatment of metastatic non-small-cell lung cancer (NSCLC)
Fact Sheet No. 178 (May 2024)
Osimertinib (Tagrisso®) with pemetrexed and platinum-based chemotherapy for the first-line treatment of advanced non-small cell lung cancer (NSCLC)
Fact Sheet No. 179 (May 2024)
Tislelizumab (Tevimbra®) monotherapy or in combination with chemotherapy for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC)
Horizon Scanning in Oncology - Fact Sheets
We are pleased to introduce you six new Fact Sheets.
Fact Sheet No. 171 (April 2024)
Fruquintinib (Fruzaqla®) as monotherapy for the treatment of metastatic colorectal cancer (mCRC)
Fact Sheet No. 172 (April 2024)
Capivasertib (Truqap®) with fulvestrant for the treatment ER-positive, HER2 negative locally advanced or metastatic breast cancer
Fact Sheet No. 173 (April 2024)
Alectinib (Alecensa®) as adjuvant treatment following complete tumour resection for adult patients with ALK positive non-small cell lung cancer (NSCLC)
Fact Sheet No. 174 (April 2024)
Nivolumab (Opdivo®) in combination with cisplatin and gemcitabine for the first-line treatment of unresectable or metastatic urothelial carcinoma
Fact Sheet No. 175 (April 2024)
Entrectinib (Rozlytrek®) as monotherapy for the treatment of solid tumours with a NTRK gene fusion
Fact Sheet No. 176 (April 2024)
Amivantamab (Rybrevant®) with carboplatin and pemetrexed for the first line treatment of advanced non-small cell lung cancer (NSCLC) with activating EGFR Exon 20 insertion mutations
Horizon Scanning in Oncology - Fact Sheets
We are pleased to introduce you three new Fact Sheets.
Fact Sheet No. 168 (March 2024)
Irinotecan hydrochloride trihydrate (Onivyde® pegylated liposomal) in combination with oxaliplatin, 5-fluorouracil (5-FU) and leucovorin (LV) for the first-line treatment of adult patients with metastatic adenocarcinoma of the pancreas
Fact Sheet No. 169 (March 2024)
Selpercatinib (Retsevmo®) as monotherapy for the treatment of advanced rearranged during transfection (RET) fusion-positive solid tumours
Fact Sheet No. 170 (March 2024)
Enzalutamide (Xtandi®) as monotherapy or in combination with androgen deprivation therapy (ADT) for the treatment of high risk biochemical recurrent (BCR) non-metastatic hormone sensitive prostate cancer (nmHSPC)
Horizon Scanning in Oncology - Fact Sheets
We are pleased to introduce you four new Fact Sheets.
Fact Sheet No. 164 (February 2024)
Tislelizumab (Tizveni®) in monotherapy or in combination with chemotherapy for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC)
Fact Sheet No. 165 (February 2024)
Retifanlimab (Zynyz®) as monotherapy for the first line treatment of patients with metastatic or recurrent locally advanced Merkel cell carcinoma
Fact Sheet No. 166 (February 2024)
Ciltacabtagene autoleucel (Carvykti®) for the treatment of relapsed and refractory multiple myeloma (MM)
Fact Sheet No. 167 (February 2024)
Pembrolizumab (Keytruda®) as pre- and post-operative treatment of resectable non small cell lung carcinoma (NSCLC)
Horizon Scanning in Oncology - Fact Sheets
We are pleased to introduce you two new Fact Sheets.
Fact Sheet No. 162 (Jänner 2024)
Idecabtagene vicleucel (Abecma®) for the treatment of adult patients with relapsed and refractory multiple myeloma (MM) who have received at least two prior therapies
Fact Sheet No. 163 (Jänner 2024)
Selpercatinib (Retsevmo®) as monotherapy is indicated for the treatment of adults and adolescents with advanced RET fusion-positive thyroid cancer
Role of Public Contributions to the Development of Health Innovations
New (pharmaceutical) products are getting increasingly more expensive. As a result of this trend accessibility of pharmaceuticals decreases. However, not all innovation can be attributed to private companies. Subsequently, the role of public institutions like universities, university spin-offs, and publicly funded biotech start-ups is largely being disregarded at the price negotiations. Public funding in the form of research grants, tax incentives, utilisation of clinical infrastructure or regulatory measures make a major contribution.
Article 57 of the proposed Pharmaceutical Legislation (PL, Directive) will require market authorization applicants to publicly declare any direct financial support for R&D received from public authorities. The aim of our research (funded by EU Horizon Europe Grant Agreement Number 101095593) is to increase transparency in (pharmaceutical) R&D to mitigate the risk of market failure associated with information asymmetry by analyzing pharmaceutical R&D expenditures of bringing a new medicine to the market and which factors influence these expenditures and to identify the categories needed to capture direct or indirect public contributions to R&D, to provide a framework for standardized reporting of public contributions and to reduce ambiguity in the interpretation of “direct” and “indirect” public contributions.
The report is the first output of the project HI-PRIX (WP2, sub-deliverable 2.2).
Publication: HTA Project Report No. 158: https://eprints.aihta.at/1499/
Contact: Claudia Wild
